[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:msi1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","MSI1 Gene",33,[8,16,22,29,35,41,47,53,59,66,73,79,85,91,97,103,109,115,121,127,133,138,144,150,156,162,168,174,180,186,192,198,205],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07403721","AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H\u002FdMMR Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:18:17.950264Z","2026-05-05T02:43:26.954091Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06004245","A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:26.915489Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05784688","Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.298307Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT02332668","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051\u002FKEYNOTE-051)",[26],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:29.025230Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06974110","Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:28.849469Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07094204","A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",[12],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.482220Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07213609","A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",[26],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.666743Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07182591","A Study of DS5361b in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:27.495024Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT06824363","ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w\u002FARID1a Mu",[63],"Early Phase 1","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:26.849550Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT06651593","Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors",[70],"Phase 2","2026-08-26T02:18:45.196599Z","2026-05-05T02:35:31.676572Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06562192","Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",[12],"2026-08-26T02:19:03.581490Z","2026-07-30T01:46:14.467786Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT03526835","A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",[26],"2026-08-26T02:17:16.126291Z","2026-07-30T01:46:14.461456Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05719558","A Study of ASP1002 in Adults for Treatment of Solid Tumors",[12],"2026-08-26T02:16:05.813655Z","2026-07-24T01:27:14.892649Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05684965","XTX301 in Patients With Advanced Solid Tumors",[26],"2026-08-26T02:17:30.961790Z","2026-07-05T05:32:16.814936Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06789172","A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",[12],"2026-08-26T02:16:18.872924Z","2026-07-05T05:32:16.698119Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[26],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06796907","A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors",[26],"2026-08-26T02:15:21.365312Z","2026-05-29T15:36:40.171786Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05592626","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",[26],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:29.329011Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT05669430","A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",[26],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.900585Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07262619","EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors",[26],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.515153Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":45,"content_modified":137},"NCT04777994","Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors",[12],"2026-05-05T02:43:28.128387Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT05107674","A Study of NX-1607 in Adults With Advanced Malignancies",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:28.117316Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT04787042","Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",[26],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:27.747454Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT05176483","Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.678164Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06362369","A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",[26],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:27.135162Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT04114136","Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",[70],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:26.717214Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO",[12],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:26.680299Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05086692","A Beta-only IL-2 ImmunoTherapY Study",[26],"2026-08-26T02:18:31.164304Z","2026-05-05T02:35:31.708594Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT04198766","Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",[26],"2026-08-26T02:19:08.084946Z","2026-07-30T01:46:14.442744Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06349642","Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform",[],"2026-08-26T02:17:03.534765Z","2026-05-13T02:55:06.483978Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT06200155","Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy",[70],"2026-08-26T02:16:06.684983Z","2026-05-05T02:43:27.954285Z",{"nct_id":199,"title":200,"phases":201,"status":202,"updated_at":203,"content_modified":204},"NCT05787587","A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:00:20.303350Z","2026-05-05T02:43:27.758641Z",{"nct_id":206,"title":207,"phases":208,"status":202,"updated_at":209,"content_modified":210},"NCT03935893","Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers",[70],"2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.987294Z"]